Prostate Cell News

Prostate Cell News is an online resource summarizing the latest prostate cell research.

Collagen Signaling and Matrix Stiffness Regulate Multipotency in Glandular Epithelial Stem Cells in Mice

December 18, 2024

[Nature Communications] Researchers found that Collagen I expression was commonly upregulated in adult basal stem cells (BaSCs) across the different multipotent conditions. Increasing collagen concentration or stiffness of the ECM promoted BaSC multipotency in mammary gland and prostate organoids.

Patient-Reported Outcomes of Rezvilutamide Versus Bicalutamide in Combination with Androgen Deprivation Therapy in High-Volume Metastatic Hormone-Sensitive Prostate Cancer Patients (CHART): A Randomized, Phase III...

December 18, 2024

[Signal Transduction and Targeted Therapy] The randomized Phase III CHART trial revealed that rezvilutamide plus androgen deprivation therapy in high-volume, metastatic, hormone-sensitive prostate cancer significantly enhanced radiographic progression-free and overall survival than bicalutamide.

Mitochondrial Unfolded Protein Response-Dependent β-Catenin Signaling Promotes Neuroendocrine Prostate Cancer

December 17, 2024

[Oncogene] Genetic deletion and pharmacological inhibition of the main chaperone of the mitochondrial unfolded protein response heat shock protein 60 reduced neuroendocrine prostate cancer (NEPC) growth in vivo as well as reverted NEPC cells to a more epithelial-like state.

Canonical Androgen Response Element Motifs Are Tumor Suppressive Regulatory Elements in the Prostate

December 16, 2024

[Nature Communications] Researchers discovered that activating androgen response elements (ARE) promoted differentiation and growth-suppressive transcription, potentially leading to androgen receptor prostate cancer (PCa) cell death, while ARE repression was tolerated by PCa cells but deleterious to normal prostate cells.

The Oncogenic lncRNA MIR503HG Suppresses Cellular Senescence Counteracting Supraphysiological Androgen Treatment in Prostate Cancer

December 16, 2024

[Journal of Experimental & Clinical Cancer Research] A large patient cohort analysis showed that MIR503HG was overexpressed in metastatic prostate cancer and was associated with reduced patient survival, indicating its potential oncogenic role.

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase III Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

December 13, 2024

[Candel Therapeutics, Inc.] The Phase III clinical trial of CAN-2409 in intermediate-to-high-risk, localized prostate cancer met its primary endpoint, by demonstrating statistically significant improvement in disease-free survival in patients who received CAN-2409 plus prodrug combined with standard of care compared to standard of care alone.

Rarγ-Foxa1 Signaling Promotes Luminal Identity in Prostate Progenitors and Is Disrupted in Prostate Cancer

December 13, 2024

[EMBO Reports] Leveraging prostate organoid technology, researchers showed that retinoic acid signaling orchestrates the commitment of adult mouse prostate progenitors to glandular identity, epithelial barrier integrity, and specification of prostatic lumen.

Recent and Future Developments in the Use of Poly (ADP-Ribose) Polymerase Inhibitors for Prostate Cancer

December 13, 2024

[European Urology Oncology] Researchers examine the latest developments in clinical trials testing poly (ADP-ribose) polymerase inhibitors for advanced prostate cancer and their emerging role in earlier disease settings.

AR Alterations Inform Circulating Tumor DNA Detection in Metastatic Castration Resistant Prostate Cancer Patients

December 12, 2024

[Nature Communications] Scientists developed a custom targeted cell free DNA (cfDNA) sequencing assay, named AR-ctDETECT, to detect circulating tumor DNA in limiting plasma cfDNA available from metastatic CRPC patients in the Alliance A031201 randomized Phase III trial of enzalutamide with or without abiraterone.

NCCN Announces Funding for a Prostate Cancer Research Project

December 12, 2024

[NCCN^®] The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (announced funding of a project that will underpin innovative research on optimal management of side effects secondary to treatment with poly ADP ribose polymerase inhibitors.

Plasma Cell-Free DNA Chromatin Immunoprecipitation Profiling Depicts Phenotypic and Clinical Heterogeneity in Advanced Prostate Cancer

December 10, 2024

[Cancer Research] Investigators analyzed activating promoter- and enhancer-associated H3K4me2 from cfDNA in metastatic prostate cancer enriched for divergent patterns of metastasis and diverse clinical presentation.

Castrate-Resistant Prostate Cancer Response to Taxane Is Determined by an HNF1-Dependent Apoptosis Resistance Circuit

December 9, 2024

[Cell Reports Medicine] Scientists performed a high-throughput screen across a cohort of 30 diverse patient-derived CRPC organoids to a library of 78 drugs.

Published since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing of prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.